8 companies

Showing 1–8 of 8 companies

Orchard Therapeutics

Orchard Therapeutics develops ex vivo autologous HSC gene therapies for rare genetic diseases; its Libmeldy is the first FDA-approved therapy for metachromatic leukodystrophy.

1 open job

Anjarium Biosciences

Swiss Series A company supplying cell-free synthetic DNA constructs and the Hybridosome™ nanoparticle delivery technology for non-viral gene therapy applications.

1 open job

MeiraGTx

MeiraGTx is a clinical-stage genetic medicine company developing therapies for diseases using viral vectors and a riboswitch gene regulation platform.

ProtaGene

ProtaGene is a bioanalytical CRO providing protein and gene therapy analytics, assay development and regulatory support to biopharma clients across four sites in Europe and North America.

RoslinCT

RoslinCT is a cell and gene therapy CDMO providing process development and clinical and commercial manufacturing, with facilities in Edinburgh and Boston.

Nucleome Therapeutics

Nucleome Therapeutics is an Oxford-based biotech company using 3D genome sequencing and machine learning to decode the dark genome and develop precision medicines for immune-mediated inflammatory diseases.

GlycoEra AG

GlycoEra AG develops biologics that selectively degrade disease-driving circulating proteins such as autoantibodies, led by GE8820 for pathogenic IgG4 in autoimmune disease.

1 open job

Autolus

Autolus develops programmed CAR T cell therapies for cancer and autoimmune disease; its AUCATZYL (obe-cel) therapy received FDA approval in November 2024.

1 open job

8 companies

Orchard Therapeutics

Anjarium Biosciences

MeiraGTx

ProtaGene

RoslinCT

Nucleome Therapeutics

GlycoEra AG

Autolus

Browse by market